<p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）的股票评级在周四的报告中被威廉·布莱尔的股票分析师重申为 “跑赢大盘”，RTT 新闻报道。</p>
<p>获取 <strong>Guardant Health</strong> 的最新提醒：</p>
<ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
<p>GH 已经成为其他多份研究报告的主题。雷蒙德·詹姆斯金融公司将 Guardant Health 的目标价从 59.00 美元上调至 61.00 美元，并在 7 月 31 日的研究报告中给予该公司 “跑赢大盘” 的评级。加拿大丰业银行将 Guardant Health 的目标价从 57.00 美元上调至 60.00 美元，并在 7 月 31 日的研究报告中给予该公司 “行业跑赢大盘” 的评级。瑞穗证券将 Guardant Health 的目标价从 60.00 美元上调至 65.00 美元，并在 6 月 13 日的研究报告中给予该股票 “跑赢大盘” 的评级。摩根大通将 Guardant Health 的目标价从 60.00 美元上调至 70.00 美元，并在周四的研究报告中给予该公司 “增持” 的评级。最后，瑞银集团将 Guardant Health 的目标价从 70.00 美元上调至 80.00 美元，并在周四的研究报告中给予该股票 “买入” 的评级。一位分析师给予该股票 “强烈买入” 的评级，二十一位分析师给予该股票 “买入” 的评级。根据 MarketBeat 的数据，Guardant Health 的共识评级为 “买入”，平均目标价为 62.95 美元。</p>
<p><strong>查看我们对 Guardant Health 的最新股票分析</strong></p>
<h2>Guardant Health 价格表现</h2>
<ul>
<li>解读颠覆：凯西·伍德的最新投资策略</li>
</ul>
<p>周四中午交易时，纳斯达克：GH 的股票上涨了 3.23 美元，达到 60.90 美元。该公司交易了 2,124,473 股，而其平均交易量为 2,396,983 股。该公司的 50 日移动平均价格为 55.08 美元，200 日移动平均价格为 48.55 美元。Guardant Health 的 52 周最低价为 20.14 美元，52 周最高价为 68.00 美元。该公司的市值为 75.9 亿美元，市盈率为-18.14，贝塔值为 1.46。</p>
<p>Guardant Health（纳斯达克：GH - 获取免费报告）最近一次发布财报是在 7 月 30 日，报告显示该公司本季度每股收益为（0.44 美元），超出分析师共识预期的（0.52 美元）0.08 美元。该公司本季度的收入为 2.3209 亿美元，而共识预期为 2.1119 亿美元。在去年同期，该公司每股收益为（0.84 美元）。与去年同期相比，该公司的收入增长了 31.0%。Guardant Health 已将其 2025 财年的指引设定为每股收益。研究分析师平均预测 Guardant Health 在当前财年将发布-2.9 的每股收益。</p>
<h2>内部买卖</h2>
<ul>
<li>3 只快速增长的股票分析师预计价格将翻倍</li>
</ul>
<p>在其他 Guardant Health 的新闻中，首席执行官 Amirali Talasaz 在 7 月 1 日的交易中出售了 100,000 股股票，交易均价为 50.88 美元，总交易额为 5,088,000.00 美元。出售完成后，首席执行官直接持有该公司 1,971,830 股股票，价值 100,326,710.40 美元。这笔交易代表其持股比例减少了 4.83%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Medina Manuel Hidalgo 在 9 月 12 日的交易中出售了 2,165 股 Guardant Health 股票，交易均价为 54.16 美元，总价值为 117,256.40 美元。出售后，该董事持有 851 股该公司股票，价值约 46,090.16 美元。这笔交易代表其持股比例减少了 71.78%。该交易的披露信息可在此处找到。在过去的九十天里，内部人士出售了 402,691 股公司股票，价值 23,069,965 美元。6.10% 的股票由公司内部人士持有。</p>
<h2>Guardant Health 的机构交易</h2>
<p>几家大型投资者最近增加或减少了对 GH 的持股。IFP Advisors Inc 在第二季度将其在 Guardant Health 的持股增加了 120.1%。IFP Advisors Inc 现在拥有 612 股该公司的股票，价值 33,000 美元，此前在上个季度增持了 334 股。Signaturefd LLC 在第二季度将其在 Guardant Health 的持股增加了 50.5%。Signaturefd LLC 现在拥有 635 股该公司的股票，价值 33,000 美元，此前在上个季度增持了 213 股。Allworth Financial LP 在第二季度将其在 Guardant Health 的持股增加了 358.4%。Allworth Financial LP 现在拥有 706 股该公司的股票，价值 37,000 美元，此前在上个季度增持了 552 股。FNY Investment Advisers LLC 在第二季度获得了 Guardant Health 的新头寸，价值 62,000 美元。最后，SVB Wealth LLC 在第一季度购买了 Guardant Health 的新股份，价值约 54,000 美元。目前 92.60% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Guardant Health 公司简介</h2>
<p>（获取免费报告）</p>
<p>Guardant Health, Inc 是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 响应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，一种为临床和生物制药客户设计的集成软件解决方案，旨在将接受检测的患者与具有潜在相关临床研究的可操作性改变相连接；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，一个用于肿瘤演变和治疗耐药性的计算机模拟研究平台，适用于各种生物标志物驱动的癌症。</p>
<h2>进一步阅读</h2>
<ul>
<li>我们更看好的五只股票，而不是 Guardant Health</li>
<li>多伦多证券交易所创业板（前身为加拿大创业交易所）</li>
<li>美光的股价反弹还没有结束：MU $190 即将到来</li>
<li>股票分红削减发生了，你准备好了吗？</li>
<li>为什么交易者在大幅反弹后加倍押注 SoundHound 股票</li>
<li>金融服务股票投资</li>
<li>锂美洲的反弹推动了其他稀土股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 $1,000 在 Guardant Health 吗？</h2>
<p>在你考虑 Guardant Health 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Guardant Health 并不在名单上。</p>
<p>虽然 Guardant Health 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>威廉·布莱尔（William Blair）重申了对 Guardant Health（NASDAQ:GH）股票的 “跑赢大盘” 评级。该股票获得了多位分析师的积极评级，价格目标被雷蒙德·詹姆斯（Raymond James）、斯科舍银行（Scotiabank）、瑞穗（Mizuho）、摩根大通（JPMorgan）和瑞银（UBS）上调。Guardant Health 的股票交易价格为 60.90 美元，市值为 75.9 亿美元。该公司报告了同比增长 31% 的收入，上一季度每股收益为（-0.44 美元）。内部交易活动包括首席执行官阿米拉利·塔拉萨兹（Amirali Talasaz）和董事梅迪纳·曼努埃尔·伊达尔戈（Medina Manuel Hidalgo）的重大出售</p>

<p>Guardant Health (NASDAQ:GH - Get Free Report)'s stock had its &#34;outperform&#34; rating reiterated by stock analysts at William Blair in a report released on Thursday,RTT News reports.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克股票代码：GH - 获取免费报告）的股票评级在周四的报告中被威廉·布莱尔的股票分析师重申为 “跑赢大盘”，RTT 新闻报道。</p>
</div><p>Get <strong>Guardant Health</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Guardant Health</strong> 的最新提醒：</p>
</div><ul>
<li>4 Healthcare Stocks With Massive Gains—and More to Come</li>
</ul>
<div class="lb-trans"><ul>
<li>4 只医疗保健股票大幅上涨——还有更多上涨空间</li>
</ul>
</div><p>GH has been the topic of a number of other research reports. Raymond James Financial raised their price objective on Guardant Health from $59.00 to $61.00 and gave the company an &#34;outperform&#34; rating in a research report on Thursday, July 31st. Scotiabank boosted their price objective on Guardant Health from $57.00 to $60.00 and gave the company a &#34;sector outperform&#34; rating in a research report on Thursday, July 31st. Mizuho lifted their price target on Guardant Health from $60.00 to $65.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, June 13th. JPMorgan Chase &amp; Co. lifted their target price on Guardant Health from $60.00 to $70.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday. Finally, UBS Group upped their price objective on Guardant Health from $70.00 to $80.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating and twenty-one have assigned a Buy rating to the stock. Based on data from MarketBeat, Guardant Health has a consensus rating of &#34;Buy&#34; and an average target price of $62.95.</p>
<div class="lb-trans"><p>GH 已经成为其他多份研究报告的主题。雷蒙德·詹姆斯金融公司将 Guardant Health 的目标价从 59.00 美元上调至 61.00 美元，并在 7 月 31 日的研究报告中给予该公司 “跑赢大盘” 的评级。加拿大丰业银行将 Guardant Health 的目标价从 57.00 美元上调至 60.00 美元，并在 7 月 31 日的研究报告中给予该公司 “行业跑赢大盘” 的评级。瑞穗证券将 Guardant Health 的目标价从 60.00 美元上调至 65.00 美元，并在 6 月 13 日的研究报告中给予该股票 “跑赢大盘” 的评级。摩根大通将 Guardant Health 的目标价从 60.00 美元上调至 70.00 美元，并在周四的研究报告中给予该公司 “增持” 的评级。最后，瑞银集团将 Guardant Health 的目标价从 70.00 美元上调至 80.00 美元，并在周四的研究报告中给予该股票 “买入” 的评级。一位分析师给予该股票 “强烈买入” 的评级，二十一位分析师给予该股票 “买入” 的评级。根据 MarketBeat 的数据，Guardant Health 的共识评级为 “买入”，平均目标价为 62.95 美元。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on Guardant Health</strong></p>
<div class="lb-trans"><p><strong>查看我们对 Guardant Health 的最新股票分析</strong></p>
</div><h2>Guardant Health Price Performance</h2>
<div class="lb-trans"><h2>Guardant Health 价格表现</h2>
</div><ul>
<li>Deciphering Disruption: Inside Cathie Wood's Latest Plays</li>
</ul>
<div class="lb-trans"><ul>
<li>解读颠覆：凯西·伍德的最新投资策略</li>
</ul>
</div><p>Shares of NASDAQ:GH traded up $3.23 during mid-day trading on Thursday, reaching $60.90. 2,124,473 shares of the company traded hands, compared to its average volume of 2,396,983. The company's 50 day moving average price is $55.08 and its 200-day moving average price is $48.55. Guardant Health has a 52 week low of $20.14 and a 52 week high of $68.00. The firm has a market cap of $7.59 billion, a PE ratio of -18.14 and a beta of 1.46.</p>
<div class="lb-trans"><p>周四中午交易时，纳斯达克：GH 的股票上涨了 3.23 美元，达到 60.90 美元。该公司交易了 2,124,473 股，而其平均交易量为 2,396,983 股。该公司的 50 日移动平均价格为 55.08 美元，200 日移动平均价格为 48.55 美元。Guardant Health 的 52 周最低价为 20.14 美元，52 周最高价为 68.00 美元。该公司的市值为 75.9 亿美元，市盈率为-18.14，贝塔值为 1.46。</p>
</div><p>Guardant Health (NASDAQ:GH - Get Free Report) last posted its earnings results on Wednesday, July 30th. The company reported ($0.44) EPS for the quarter, beating analysts' consensus estimates of ($0.52) by $0.08. The firm had revenue of $232.09 million for the quarter, compared to the consensus estimate of $211.19 million. During the same quarter in the prior year, the company posted ($0.84) earnings per share. The firm's revenue was up 31.0% compared to the same quarter last year. Guardant Health has set its FY 2025 guidance at EPS. On average, research analysts predict that Guardant Health will post -2.9 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Guardant Health（纳斯达克：GH - 获取免费报告）最近一次发布财报是在 7 月 30 日，报告显示该公司本季度每股收益为（0.44 美元），超出分析师共识预期的（0.52 美元）0.08 美元。该公司本季度的收入为 2.3209 亿美元，而共识预期为 2.1119 亿美元。在去年同期，该公司每股收益为（0.84 美元）。与去年同期相比，该公司的收入增长了 31.0%。Guardant Health 已将其 2025 财年的指引设定为每股收益。研究分析师平均预测 Guardant Health 在当前财年将发布-2.9 的每股收益。</p>
</div><h2>Insider Buying and Selling</h2>
<div class="lb-trans"><h2>内部买卖</h2>
</div><ul>
<li>3 Fast-Growing Stocks Analysts See Doubling in Price</li>
</ul>
<div class="lb-trans"><ul>
<li>3 只快速增长的股票分析师预计价格将翻倍</li>
</ul>
</div><p>In other Guardant Health news, CEO Amirali Talasaz sold 100,000 shares of the stock in a transaction that occurred on Tuesday, July 1st. The shares were sold at an average price of $50.88, for a total transaction of $5,088,000.00. Following the completion of the sale, the chief executive officer directly owned 1,971,830 shares of the company's stock, valued at $100,326,710.40. This trade represents a 4.83% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Medina Manuel Hidalgo sold 2,165 shares of Guardant Health stock in a transaction on Friday, September 12th. The stock was sold at an average price of $54.16, for a total value of $117,256.40. Following the sale, the director owned 851 shares of the company's stock, valued at approximately $46,090.16. This trade represents a 71.78% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 402,691 shares of company stock valued at $23,069,965. 6.10% of the stock is owned by corporate insiders.</p>
<div class="lb-trans"><p>在其他 Guardant Health 的新闻中，首席执行官 Amirali Talasaz 在 7 月 1 日的交易中出售了 100,000 股股票，交易均价为 50.88 美元，总交易额为 5,088,000.00 美元。出售完成后，首席执行官直接持有该公司 1,971,830 股股票，价值 100,326,710.40 美元。这笔交易代表其持股比例减少了 4.83%。该交易已在向 SEC 提交的文件中披露，相关信息可通过 SEC 网站获取。此外，董事 Medina Manuel Hidalgo 在 9 月 12 日的交易中出售了 2,165 股 Guardant Health 股票，交易均价为 54.16 美元，总价值为 117,256.40 美元。出售后，该董事持有 851 股该公司股票，价值约 46,090.16 美元。这笔交易代表其持股比例减少了 71.78%。该交易的披露信息可在此处找到。在过去的九十天里，内部人士出售了 402,691 股公司股票，价值 23,069,965 美元。6.10% 的股票由公司内部人士持有。</p>
</div><h2>Institutional Trading of Guardant Health</h2>
<div class="lb-trans"><h2>Guardant Health 的机构交易</h2>
</div><p>Several large investors have recently added to or reduced their stakes in GH. IFP Advisors Inc lifted its stake in Guardant Health by 120.1% during the 2nd quarter. IFP Advisors Inc now owns 612 shares of the company's stock worth $33,000 after acquiring an additional 334 shares in the last quarter. Signaturefd LLC boosted its stake in shares of Guardant Health by 50.5% in the second quarter. Signaturefd LLC now owns 635 shares of the company's stock valued at $33,000 after buying an additional 213 shares in the last quarter. Allworth Financial LP raised its holdings in Guardant Health by 358.4% during the second quarter. Allworth Financial LP now owns 706 shares of the company's stock worth $37,000 after purchasing an additional 552 shares during the last quarter. FNY Investment Advisers LLC acquired a new position in Guardant Health in the second quarter valued at $62,000. Finally, SVB Wealth LLC purchased a new stake in Guardant Health during the first quarter valued at about $54,000. 92.60% of the stock is currently owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对 GH 的持股。IFP Advisors Inc 在第二季度将其在 Guardant Health 的持股增加了 120.1%。IFP Advisors Inc 现在拥有 612 股该公司的股票，价值 33,000 美元，此前在上个季度增持了 334 股。Signaturefd LLC 在第二季度将其在 Guardant Health 的持股增加了 50.5%。Signaturefd LLC 现在拥有 635 股该公司的股票，价值 33,000 美元，此前在上个季度增持了 213 股。Allworth Financial LP 在第二季度将其在 Guardant Health 的持股增加了 358.4%。Allworth Financial LP 现在拥有 706 股该公司的股票，价值 37,000 美元，此前在上个季度增持了 552 股。FNY Investment Advisers LLC 在第二季度获得了 Guardant Health 的新头寸，价值 62,000 美元。最后，SVB Wealth LLC 在第一季度购买了 Guardant Health 的新股份，价值约 54,000 美元。目前 92.60% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Guardant Health Company Profile</h2>
<div class="lb-trans"><h2>Guardant Health 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.</p>
<div class="lb-trans"><p>Guardant Health, Inc 是一家精准肿瘤学公司，在美国和国际上提供血液和组织检测、数据集和分析。该公司提供 Guardant360；Guardant360 LDT；Guardant360 CDx 测试；Guardant360 响应测试；Guardant360 TissueNext 测试；GuardantINFINITY 测试；GuardantConnect，一种为临床和生物制药客户设计的集成软件解决方案，旨在将接受检测的患者与具有潜在相关临床研究的可操作性改变相连接；GuardantOMNI 测试用于晚期癌症；以及 GuardantINFORM，一个用于肿瘤演变和治疗耐药性的计算机模拟研究平台，适用于各种生物标志物驱动的癌症。</p>
</div><h2>Further Reading</h2>
<div class="lb-trans"><h2>进一步阅读</h2>
</div><ul>
<li>Five stocks we like better than Guardant Health</li>
<li>TSX Venture Exchange (Formerly Canadian Venture Exchange)</li>
<li>Micron’s Stock Price Rally Is Not Over: MU $190 Is Coming Soon</li>
<li>Stock Dividend Cuts Happen Are You Ready?</li>
<li>Why Traders Are Doubling Down on SoundHound Stock After Big Rally</li>
<li>Financial Services Stocks Investing</li>
<li>Lithium Americas Rally Lifts Other Rare Earth Stocks</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Guardant Health</li>
<li>多伦多证券交易所创业板（前身为加拿大创业交易所）</li>
<li>美光的股价反弹还没有结束：MU $190 即将到来</li>
<li>股票分红削减发生了，你准备好了吗？</li>
<li>为什么交易者在大幅反弹后加倍押注 SoundHound 股票</li>
<li>金融服务股票投资</li>
<li>锂美洲的反弹推动了其他稀土股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0g" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NASDAQ&amp;Symbol=GH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。请将任何问题或意见发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Guardant Health Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 $1,000 在 Guardant Health 吗？</h2>
</div><p>Before you consider Guardant Health, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Guardant Health 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前购买……而 Guardant Health 并不在名单上。</p>
</div><p>While Guardant Health currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Guardant Health 目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

William Blair 重申对 Guardant Health（GH）的 “表现优于大盘” 评级